Skip to content

BELGOPHARMA

Active Private limited companyfounded 2021active for 5 yearsBergense Steenweg 1160, 1070 AnderlechtKBO/BCE: BE 0762.935.682

Lifetime

5 annual accounts with figures on one time axis
peak of €1.8m in 2024
€754,756▼ 57.3%
peak of €1.2m in 2024
€412,067▼ 66.6%
peak of €2.7m in 2025
€2.7m▲ 18.2%
€957,585▼ 9.1%
Board2 names since 2021
1 director
Documentsfilings and deeds
22-07-20269 days before the deadline
2025abbreviated format
Gross margin from €1.8m to €754,756Result from €1.2m to €412,067Equity from €2.3m to €2.7mInvestments €622,911Cash from €1.9m to €1.3m

Key points

from the 2025 annual accounts

Equity

€2.7m ▲ 18.2%

BELGOPHARMA has made a profit in every financial year since 2021.

Result

€412,067 ▼ 66.6%
€1.2m2024€412,0002025

The result fell in 2025: different schema filed.

Turnover

≈ €3.8m estimated

The accounts state no turnover.

Investments

€22,911 5.9 times depreciation
202220242025

Green is investment, beige is depreciation.

Filings

5 annual accounts 4 late
AprilJune31 JulyOctober20222024

The 2021 accounts came in latest, 30 days after the end of the period.

Position in the sector

€2.7m

More equity than 90% of companies in wholesale trade. Sector median €493,889 · 10,750 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,784 companies had the same profile as BELGOPHARMA has now. Each dot stands for 17 companies, two years later.

96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,784 companies, not a prediction for BELGOPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • deed of 14-02-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0762935682
resigns as director Transfer of shares from to · General meeting of 28-02-2022 · Gazette deed
Incorporation Founding capital of €6,200, 1,000 shares · Founded by and (director) and (director) appointed · published on 08-02-2021 · Gazette deed
First establishment Bergense Steenweg 1160, Anderlecht
All 14 events

Comparable companies

same main activity, similar in size and age
Company
BELGOPHARMA Anderlecht €3.6m €0.8m 73.6% -
PAMSANTE BENELUX Brussels €2.4m €1.1m 34.9% 4
LIFEXA Schaerbeek €2.9m €0.8m 49.5% 4.8
Neuraxpharm Belgium Saint-Josse-ten-Noode €3.1m €0.8m -30.9% 4.8
COSMEX Tubize €5.2m €1.1m 7.8% 12.7
Pharma Boulevard Lier €2.3m €1.0m 21.7% 12
SOLVUS Ghent €2.5m €0.5m 16.3% 1

These companies have the same main activity as BELGOPHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €2.3m and €5.2m, founded between 2019 and 2022.

Official details

Source: KBO
Status
Active since 04-02-2021Normal situation
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Establishment unit
2.357.806.7141070 Anderlecht, since 04-02-2021
Financial year end
31 December
Peppol
Reachable since 04-12-2025
Company details

Annual accounts 2025

€3.6m▲ 9.5%
Filing
Filed on 22-07-2026, 9 days before the end of the filing period
Financials

Insights on BELGOPHARMA

BELGOPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €3,342 in 2021 to €754,756 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BELGOPHARMA

What is the company number of BELGOPHARMA?
The company number of BELGOPHARMA is 0762.935.682. The VAT number is the same number with BE in front: BE 0762.935.682.
Where is BELGOPHARMA based?
The registered office is at Bergense Steenweg 1160, 1070 Anderlecht.Company details
What does BELGOPHARMA do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of BELGOPHARMA?
BELGOPHARMA is a private limited company (BV).
When was BELGOPHARMA founded?
BELGOPHARMA was founded on 04-02-2021.
Is BELGOPHARMA still active?
Yes, BELGOPHARMA is an active enterprise in the KBO register.
What is the turnover of BELGOPHARMA?
The turnover in financial year 2025 is ≈ €3.8m. This figure is estimated from the gross margin of €754,756 and 35 comparable companies (NACE 464). It probably lies between €2.6m and €5.2m. In financial year 2022 turnover was €3.8m.Financials
Is BELGOPHARMA profitable?
In financial year 2025, BELGOPHARMA made a profit of €412,067.
Where can I find the annual accounts of BELGOPHARMA?
BELGOPHARMA filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BELGOPHARMA due?
BELGOPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.